Literature DB >> 29391190

Epidermal growth factor receptor/extracellular signal-regulated kinase pathway enhances mineralocorticoid receptor transcriptional activity through protein stabilization.

Yuko Mitsuishi1, Hirotaka Shibata2, Isao Kurihara1, Sakiko Kobayashi1, Kenichi Yokota1, Ayano Murai-Takeda1, Takeshi Hayashi3, Rie Jo1, Toshifumi Nakamura1, Mitsuha Morisaki1, Hiroshi Itoh1.   

Abstract

Activation of mineralocorticoid receptor (MR) is evoked by aldosterone, and it induces hypertension and cardiovascular disease when it's concomitant with excessive salt loading. We have proposed the notion of "MR-associated hypertension", in which add-on therapy of MR blockers is effective even though serum aldosterone level is within normal range. To elucidate its underlying molecular mechanism, we focused on the effect of epidermal growth factor receptor (EGFR)/extracellular signal-regulated kinase (ERK) activation on MR activity. Epidermal growth factor (EGF) administration increased MR transcriptional activity through EGFR/ERK pathway and increased protein level by counteracting MR ubiquitylation in vitro. EGF administration in vivo also increased MR protein level and target gene expression in kidney, which were decreased by EGFR inhibitor. In addition, the administration of EGFR inhibitor lowered systolic blood pressure and MR activity in DOCA/salt-treated mice. In conclusion, EGFR/ERK pathway activation is considered as one of the underlying mechanisms of aberrant MR activation and EGFR/ERK pathway blockade could be an alternative approach for the prevention of MR-related cardiovascular events.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Epidermal growth factor receptor; Extracellular signal-regulated kinase pathway; Mineralocorticoid receptor

Mesh:

Substances:

Year:  2018        PMID: 29391190     DOI: 10.1016/j.mce.2018.01.007

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  5 in total

1.  Lysine-specific demethylase 1 as a corepressor of mineralocorticoid receptor.

Authors:  Nao Kohata; Isao Kurihara; Kenichi Yokota; Sakiko Kobayashi; Ayano Murai-Takeda; Yuko Mitsuishi; Toshifumi Nakamura; Mitsuha Morisaki; Takahide Kozuma; Takuto Torimitsu; Miki Kawai; Hiroshi Itoh
Journal:  Hypertens Res       Date:  2022-02-17       Impact factor: 3.872

2.  Mechanisms of mineralocorticoid receptor-associated hypertension in diabetes mellitus: the role of O-GlcNAc modification.

Authors:  Rie Jo; Hirotaka Shibata; Isao Kurihara; Kenichi Yokota; Sakiko Kobayashi; Ayano Murai-Takeda; Yuko Mitsuishi; Takeshi Hayashi; Toshifumi Nakamura; Hiroshi Itoh
Journal:  Hypertens Res       Date:  2022-10-14       Impact factor: 5.528

Review 3.  "Greedy Organs Hypothesis" for sugar and salt in the pathophysiology of non-communicable diseases in relation to sodium-glucose co-transporters in the intestines and the kidney.

Authors:  Hiroshi Itoh; Masami Tanaka
Journal:  Metabol Open       Date:  2022-02-09

4.  Upregulation of Mineralocorticoid Receptor Contributes to Development of Salt-Sensitive Hypertension after Ischemia-Reperfusion Injury in Rats.

Authors:  Takumi Matsumoto; Shigehiro Doi; Ayumu Nakashima; Takeshi Ike; Kensuke Sasaki; Takao Masaki
Journal:  Int J Mol Sci       Date:  2022-07-15       Impact factor: 6.208

Review 5.  OPALS: A New Osimertinib Adjunctive Treatment of Lung Adenocarcinoma or Glioblastoma Using Five Repurposed Drugs.

Authors:  Richard E Kast; Marc-Eric Halatsch; Rafael Rosell
Journal:  Cells       Date:  2021-05-10       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.